CClinicalTrials.gg
WithdrawnNCT04117373Updated Mar 6, 2020

Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database

An observational study in Skin Cancer, Mohs Micrographic Surgery and Interpolated Flap Repair, sponsored by University of Pennsylvania. Withdrawn at 1 site in United States. Open to participants aged 1 Year to 99 Years. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by University of Pennsylvania · Observational

Why this study was withdrawn
The researchers were unable to answer the study question by utilizing the insurance claims database.
Study type
Observational
Model
Ecologic or community
Time perspective
Retrospective
Enrollment
0
Ages
1 Year to 99 Years
Sex
All
01

Study summary

Mohs micrographic surgery (MMS) followed by skin reconstruction has been widely accepted for treatment of many skin cancers. To further characterize the trends in MMS and reconstruction for skin cancer, a retrospective analysis will be performed using the Optum© Clinformatics® DataMart de-identified commercial claims database from 2001-2016. The findings may provide critical data for future prospective studies in skin cancer treatments.

02

Conditions studied

  • Skin Cancer
  • Mohs Micrographic Surgery
  • Interpolated Flap Repair

Browse trials for

03

In context

Skin Neoplasms

582 studies on the registry are indexed under Skin Neoplasms; 114 are open to participants now.

Browse Skin Neoplasms studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 99 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population was conveniently sampled from the compilation of de-identified claims in the Optum© Clinformatics® database using ICD9 and ICD10 codes specific for skin cancer and linking them to specific CPT codes for interpolated flap repair, a reconstructive skin surgery. The investigator's population is composed of >7,000 patients across the United States who received a skin cancer diagnosis and this procedure between 2001 and 2016.

Inclusion criteria

  • All patients in the Optum© Clinformatics® database who have an ICD9 or ICD10 code for skin cancer and a corresponding CPT code specific for interpolated flap reconstruction

Exclusion criteria

Exclusion criteria:

  • All patients for whom cost data is missing in the Optum© Clinformatics® DataMart
05

Study design

Observational model
Ecologic or community
Time perspective
Retrospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.

06

What researchers measure

Primary outcomes

  1. Primary cost

    How does interpolation flap procedure cost differ across settings

    Time frame: Claims from 2001-2016 will be analyzed

Secondary outcomes

  1. Predictors of inpatient vs. outpatient procedure

    How does medical specialty or geographical location predict where the procedure is performed

    Time frame: Claims from 2001-2016 will be analzyed

07

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04117373
Lead sponsor
University of Pennsylvania
Responsible party
Sponsor
First posted
Oct 7, 2019
Start date
Jul 1, 2019
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Mar 6, 2020

Study contacts

Jeremy Etzkorn, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion